XORTX Therapeutics (XRTX)

• Market cap: $3.62M
• 1 day: -2.79%
• 5 days: -1.88%
• 1 month: -19.62%
• 3 months: -0.48%
• 6 months: -29.15%
• Year to date: -26.67%
• 1 year: -51.4%
• 5 years: -99.84%
• 10 years: -99.84%
• Sector: Healthcare
• Industry: Biotechnology

About: XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Employees: 3